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ORIGINAL ARTICLE
The MutSb complex is a modulator of p53-driven tumorigenesis
through its functions in both DNA double-strand break repair
and mismatch repair
JMM van Oers1,4, Y Edwards1,4, R Chahwan1, W Zhang2, C Smith3, X Pechuan3, S Schaetzlein1, B Jin1, Y Wang1, A Bergman3,
MD Scharff1 and W Edelmann1
Loss of the DNA mismatch repair (MMR) protein MSH3 leads to the development of a variety of tumors in mice without signiﬁcantly
affecting survival rates, suggesting a modulating role for the MutSb (MSH2-MSH3) complex in late-onset tumorigenesis. To better
study the role of MSH3 in tumor progression, we crossed Msh3 / mice onto a tumor predisposing p53-deﬁcient background.
Survival of Msh3/p53 mice was not reduced compared with p53 single mutant mice; however, the tumor spectrum changed
signiﬁcantly from lymphoma to sarcoma, indicating MSH3 as a potent modulator of p53-driven tumorigenesis. Interestingly,
Msh3 / mouse embryonic ﬁbroblasts displayed increased chromatid breaks and persistence of gH2AX foci following ionizing
radiation, indicating a defect in DNA double-strand break repair (DSBR). Msh3/p53 tumors showed increased loss of heterozygosity,
elevated genome-wide copy-number variation and a moderate microsatellite instability phenotype compared with Msh2/p53
tumors, revealing that MSH2-MSH3 suppresses tumorigenesis by maintaining chromosomal stability. Our results show that the
MSH2-MSH3 complex is important for the suppression of late-onset tumors due to its roles in DNA DSBR as well as in DNA MMR.
Further, they demonstrate that MSH2-MSH3 suppresses chromosomal instability and modulates the tumor spectrum in
p53-deﬁcient tumorigenesis and possibly has a role in other chromosomally unstable tumors as well.
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INTRODUCTION
DNA mismatch repair (MMR) complexes function primarily in
the detection and repair of mismatched bases that result from
erroneous replication. Two heterodimeric MutS homolog (MSH)
complexes, consisting of either MSH2-MSH6 (MutSa) or MSH2-
MSH3 (MutSb), are responsible for the recognition of these
mismatched bases. MSH2-MSH6 binds to single base–base
mismatches and small insertions/deletions, whereas MSH2-MSH3
has a higher afﬁnity for X2 base insertions/deletions.1,2 Germline
mutations in MSH2 and MSH6 but not MSH3 are responsible for
hereditary non-polyposis colorectal cancer/Lynch syndrome
(HNPCC/LS); however, an (A)8 tract in the coding region of
MSH3 was found to be frequently affected by frameshift mutations
in MMR-deﬁcient colorectal tumors, resulting in the loss of
MSH3 protein expression.3 In addition to its role in MMR, yeast
studies revealed that during non-conservative homologous re-
combination, the MSH2-MSH3 complex is required to remove
nonhomologous DNA ends during both the initiation of gene
conversion and the resolution of single-strand annealing (SSA)
intermediates that are initiated by a double-strand break (DSB).4,5
SSA is a subset of the homologous recombination pathway for
repairing spontaneous and induced DSBs that arise between
repeated sequences occurring in cis. MSH2 and MSH3 recognize
and stabilize the nonhomologous 30 tails at the junction of double-
stranded and single-stranded DNA to aid in either the recruitment
or cleavage activity of Rad1-Rad10.6 Although the mechanistic
contribution of MSH3 in MMR and double-strand break repair
(DSBR) was thought to be overlapping, recent studies have shown
that these two MSH3 activities are molecularly distinct.7 MSH2-
MSH3 is also involved in triplet repeat (CAG CTG) expansion
diseases such as Huntington and myotonic dystrophy, and it has
been shown in several mouse models that MSH2 and MSH3 are
absolutely required to generate these expansions.8–12
Previous observations showed that inactivation of Msh3 in mice
leads to a moderate defect in the repair of insertion/deletion but
not base–base mismatches,13 which might explain the absence of
MSH3 mutations in HNPCC/LS families. Among other tumors,
Msh3 / mice developed gastrointestinal tumors late in life,
which corresponds with loss of MSH3 expression in late-onset
sporadic colorectal cancer in humans.14 In human cancers, loss of
MSH3 is associated with an (microsatellite instability) MSI-low (MSI-
L) phenotype at dinucleotide repeats and elevated microsatellite
alterations at selected tetranucleotide repeats (EMAST).15,16 Loss or
silencing of MSH3 also frequently occurs in a variety of other
cancers, including non-small cell lung,17 ovarian, bladder,18 and
breast19 cancer. MSH3 polymorphisms were found to be associated
with sporadic colorectal,14,20,21 prostate,22 and lung23 cancer. These
ﬁndings correlate with a recent report that unlike MutSa, the
MutSb complex is abundant in the majority of mouse tissues.24
Taken together, these studies indicate that MSH2-MSH3 might be
important for tumor suppression in multiple tissues and especially
in cases of late-onset tumorigenesis.
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Previous studies in mice showed that loss of Msh2 is sufﬁcient to
initiate and signiﬁcantly accelerate tumorigenesis, especially in p53-
deﬁcient mice, and that tumorigenesis is associated with an MSI-
high (MSI-H) phenotype.25 The MSH2-MSH6 complex is essential for
the repair of base/base mismatches, and loss of either MSH2 or
MSH6 therefore results in generation of a severe mutator phenotype
and early-onset cancers. In contrast, the absence of MSH3mutations
in early-onset HNPCC/LS tumors and the late-onset tumor
phenotype in Msh3 / mice indicate that MSH3 is likely not
involved in tumor initiation. To determine a possible role for MSH2-
MSH3 in tumor progression, we crossed Msh3-null mice onto the
tumor predisposing p53-null background to create cohorts of both
Msh3 /p53 / and Msh3 /p53þ / mice, compared their
cancer predisposition phenotype with MMR-deﬁcient Msh2/p53-
mutant mice and analyzed the underlying molecular mechanisms.
Although the effects of both Msh2- and Msh3-deﬁciency manifest
from the earliest stages of life, tumor onset in Msh3 /p53 /
mice occurred later in life in contrast to the early-onset
tumorigenesis in Msh2 /p53 / mice. We found that because
of its role in DSBR in addition to MMR, loss of Msh3 alters the tumor
spectrum in p53-mutant mice by modulating the characteristics of
the chromosomal instability (CIN) phenotype, resulting in elevated
sarcomagenesis. We conclude that germline mutations in Msh3 can
cause late-onset tumorigenesis with various genomic signatures and
modulate the tumor spectrum on cancer predisposing backgrounds.
RESULTS
Altered cancer phenotype and elevated sarcomagenesis in Msh3/
p53-mutant mice
To accelerate tumorigenesis in Msh3-null mice and study tumor
progression, we intercrossed Msh3þ / - and p53þ / -knockout
mice and generated two cohorts of mutant mice carrying homo-
zygous mutations in Msh3 and either homozygous (Msh3 /
p53 / ) or heterozygous (Msh3 /p53þ / ) mutations in p53.
To compare loss of Msh3 with the classic MMR phenotype,
additional Msh2 /p53 / and Msh2 /p53þ / cohorts were
generated by intercrossing Msh2þ / and p53þ / mice.
Msh3 /p53 / double-mutant mice showed reduced survi-
val (median survival time 5 months, Figure 1a) when compared
with Msh3 / alone (22 months),13 but not when compared
with p53 / single-mutant mice (P¼ 0.31, Figure 1a). Msh3 /
p53þ / and p53þ / mice also showed similar survival rates
(P¼ 0.11), suggesting that loss of Msh3 does not contribute to
the initiation or acceleration of tumorigenesis. In contrast,
Msh2 /p53 / and Msh2 /p53þ / mice showed
Figure 1. Loss of Msh3 modifies tumor phenotype of p53-null mice. (a) Tumor-free survival was significantly different for Msh2 /p53 / and
p53 / mice (Po0.001) and for Msh2 /p53þ / and p53þ / mice (Po0.001). In contrast, survival was similar for Msh3 /p53 / and p53 /
mice (P¼ 0.31) and for Msh3 /p53þ / and p53þ / mice (P¼ 0.11). Dashed lines, Msh2/p53 genotypes; solid lines, Msh3/p53 genotypes;
dotted lines, single p53 genotypes. (b) Tumor type and incidence in mice with different Msh2, Msh3 and p53 genotypes. The percentage of
sarcomas is increased in Msh3 /p53 / and Msh3 /p53þ / mice compared with p53 / and p53þ / mice, respectively (P¼ 0.04). Also,
the carcinoma phenotype includes a small number of small intestinal tumors (Msh3 /p53 / , 1; Msh3 /p53þ / , 2). (c) Microsatellite
instability (MSI) analysis of tumors at the dinucleotide loci D7Mit91 and D17Mit123, determined by the number of unstable alleles divided by
the total number of alleles scored. (d) Loss of heterozygosity (LOH) of the wild-type p53 allele (*) was demonstrated in Msh2 /p53þ / or
Msh3 /p53þ / tumor samples using PCR (see also Table 1). Upper band, wild-type allele (540bp); lower band, p53-null allele (480bp).
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signiﬁcantly reduced survival compared with p53 / (2 vs 6
months, Po0.001) and p53þ / (5 vs 16 months, Po0.001) mice,
respectively, conﬁrming the strong tumorigenic MMR-deﬁcient
phenotype that has previously been described for Msh2 / ,26–28
Msh2 /p53 / 25 and Msh2 /p53þ / 29 mice.
The tumor spectrum of p53 / mice is dominated by
lymphomas, but also includes sarcomas and carcinomas.30
Surprisingly, loss of Msh3 induced a signiﬁcant shift in the
distribution of the various tumor types in p53-mutant mice: twice
as many sarcomas were found in Msh3 /p53 / (32 vs 17%,
P¼ 0.04) and Msh3 /p53þ / mice (53 vs 30%, P¼ 0.04,
Figure 1b) compared with tumors from p53 / and p53þ /
mice, respectively. In contrast, nearly 100% of MMR-deﬁcient
Msh2 /p53 / and Msh2 /p53þ / mice succumbed to
thymic lymphoma. Only a small number of Msh3/p53 mice
developed gastrointestinal tumors. When tumors were analyzed
for their MSI phenotype, which is the hallmark of MMR deﬁciency,
we found that most tumors from Msh2 /p53 / or Msh2 /
p53þ / mice showed MSI at the D7Mit91 and D17Mit123
dinucleotide repeats, compared with few tumors with MSI from
Msh3 /p53-mutant mice (Figure 1c). Interestingly, none of the
sarcoma samples included in the analysis (0/12) showed MSI. The
MSI-L tumor phenotype indicates that defective MMR of insertion/
deletion mutations is not a main mechanism in Msh3 /p53-
driven tumorigenesis.
LOH but not somatic mutation leads to loss of the wild-type p53
allele in Msh3 /p53þ / tumors
During tumorigenesis, MMR deﬁciency leads to the accumulation
of somatic mutations in tumor suppressor genes and oncogenes.
On the other hand, tumors with CIN usually display loss of
heterozygosity (LOH) of tumor suppressor genes, which is often
associated with defective DSBR pathways.31 As loss of the tumor
suppressor p53 is a critical event in tumorigenesis, we studied the
genetic mechanisms by which the remaining p53 wild-type allele
was lost in Msh3 /p53þ / and Msh2 /p53þ / tumors.
Consistent with the MMR-deﬁcient phenotype, the majority of
Msh2 /p53þ / tumors (63%, 12/19, Table 1) showed mutation
of p53. All p53 exons were sequenced, and mutations were found
in exons 4, 5, 7, 8, 9 and 11 of Msh2 /p53þ / tumors. In
contrast, no p53mutations were detected in the Msh3 /p53þ /
tumors (0/8); however, LOH at the wild-type p53 allele occurred in
almost all of the tumors (86%, 6/7) (Figure 1d and Table 1),
suggesting a possible role for MSH3 in CIN. LOH of the wild-type
p53 allele was also found in some Msh2 /p53þ / tumors (3/19,
16%), possibly reﬂecting loss of MSH2-MSH3 function in DSBR.
Msh3-deﬁcient MEFs are defective in DSBR
In yeast, MSH2-MSH3 is involved in the processing of SSA
recombination intermediates during certain forms of homologous
recombination,5 and loss of this function might result in defective
DSBR and contribute to the LOH phenotype in the tumors of
Msh2 /p53þ / and Msh3 /p53þ / mice. To investigate
whether mouse MSH3 functions as part of the MSH2-MSH3
complex in the repair of DNA breaks, we ﬁrst analyzed metaphases
of untreated primary mouse embryonic ﬁbroblast (MEF) cell lines.
Msh3 / and Msh2 / MEFs both showed a signiﬁcant increase
in chromatid breaks (Figures 2a and b), further indicating a
defective DSBR response. As the number of breaks in Msh6 /
cells was not signiﬁcantly different from that in wild-type cells
Table 1. p53 mutation and LOH in p53þ / tumors
Tumor sample Exon 4 Exon 5 Exon 7 Exon 8 Exon 9 Exon 11.1 LOH
Msh2 /p53þ /
29 del (A)7
47 del (A)7
90
66I ins (T)6
73 Q112STOP
65 null
49
48 del (C)5
66II ND del (A)5 ND ND
63 ND del (C)5 ND ND
53 ND del (G)6 ND ND
88 ND Q141STOP ND ND wt
86 ND del (A)5 ND ND
20
36 wt
41 ND del (C)5 ND ND
40 ND del (G)6 ND ND
89 wt
14
Msh3 /p53þ /
43 ND ND ND wt
42 ND ND ND wt
45 ND ND ND wt
56 ND ND ND ND
66 ND ND ND wt
54 ND ND ND ND ND
36
64 ND ND ND ND ND
15 ND ND ND ND ND ND wt
19 ND ND ND ND ND ND wt
Abbreviation: ND, not determined.
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(P¼ 0.21), loss of DSBR appears to be speciﬁcally due to the loss of
MSH2-MSH3 complex function. Notably, all genotypes showed
similar numbers of translocations.
To further analyze the observed DSBR defect, Msh3 / cells
were subjected to a low dose of ionizing radiation (1 Gy), and
efﬁcient resolution of DSBs was subsequently evaluated by
counting gH2AX foci in the cell nuclei (Figure 2c). We did not
observe a difference in the number of gH2AX foci 1 h after
irradiation (Supplementary Figure S1), which suggests that both
wild-type and Msh3 / MEFs had a comparable accumulation of
DSBs at early time points and that gH2AX signaling is intact in
Msh3 / cells. However, 2 h after irradiation, the majority of wild-
type cells (95%) showed background levels of 0–10 gH2AX foci per
nucleus in contrast to only 45% of Msh3 / cells (Supplementary
Figure S1). Even 6 h post irradiation, only 70% of Msh3 / cells
were able to adequately resolve DSBs (Po0.001, Figure 2d), and
an increase of more than 10 gH2AX foci per nucleus could be seen
in the remaining 30% of nuclei. Taken together, these data
demonstrate a moderate DSBR defect in Msh3-deﬁcient cells that
is revealed by a delay in resolving DSBs.
Msh3 deletion is associated with CIN in p53-deﬁcient tumors
To examine whether loss of MSH3 does leads to CIN during
tumorigenesis, we used spectral karyotyping (SKY) to determine
whether lymphomas of Msh3-deﬁcient mice displayed any gross
chromosomal abnormalities. In contrast to Msh2 /p53 /
tumor cells, which showed close to normal ploidy (40 chromo-
somes/cell, Table 2), Msh3 /p53 / tumor cell karyotypes
showed increased CIN characterized by signiﬁcantly increased
aneuploidy (55 chromosomes/cell, Po0.001), translocations, dele-
tions, duplications and breaks (Figure 3). No speciﬁc recurring
chromosomal aberrations were found, indicating that loss of
MSH3 induces general CIN. However, the type of chromosomal
changes between genotypes tended to be different: Msh3 /
p53 / and Msh2 /p53 / tumor cells showed about two
times more translocations compared with p53 / cells (1.2 and
0.9 vs 0.5 per cell, Table 2), suggesting that the DSBR defect
associated with loss of the MSH2-MSH3 complex that was
observed earlier contributes to this type of chromosomal
rearrangement. In contrast, a trend toward slightly higher
numbers of deletions and duplications was observed in Msh3 /
p53 / and p53 / cells compared with Msh2 /p53 / cells,
reﬂecting the aneuploidy phenotype that is associated with the
p53 / tumor background.
To study the increase in CIN in Msh3/p53 tumors in more
detail, we used the lymphoma samples that were used for SKY
analysis in array comparative genomic hybridization (aCGH) to
analyze genome-wide copy-number variation (CNV). As loss of
Msh3 induces sarcomagenesis, we also analyzed two groups
of Msh3 /p53þ / and p53 / sarcomas (Supplementary
Figure S2). Again, no increase in CNV was found to recur between
samples at speciﬁc genomic regions, indicating general CIN.
Compared with Msh2 /p53 / lymphoma samples, in which
CNV was uncommon, this type of instability was signiﬁcantly
increased in Msh3 /p53 / and p53 / lymphomas (Figure 4).
Figure 2. Loss of Msh3 induces a double-strand break repair defect. (a) Metaphase spreads from Msh2 / (left) and Msh3 / (right) mouse
embryonic fibroblasts (MEFs). Examples of chromatid breaks are magnified in insets. (b) Chromosomal aberrations were analyzed for 4100
metaphase nuclei per genotype in MEF cell lines. Average numbers of chromatid breaks and translocations are shown. (c) Three categories
of gH2AX foci accumulation were defined after staining with DAPI (blue) and anti-gH2AX antibody (red): 0–5, 6–10 and 410 foci per
nucleus. (d) Deficient double-strand break repair was defined by accumulation of gH2AX foci in Msh3 / and wild-type MEFs 6 h after
irradiation with 1Gy.
Table 2. Chromosomal aberrations from SKY analysis
Tumor
sample
No of
Cells
Average no aberrations
per cell (± 95% CI)
Chromosomes Translocations Deletions/
duplications
Msh3 /
p53 /
23 55a (51–83) 1.2 (0.4–1.9) 1.0 (0.4–1.5)
Msh2 /
p53 /
26 40 (39–41) 0.9 (0.5–1.3) 0.7 (0.2–1.2)
p53 / 17 51 (51–54) 0.5 (0.1–0.8) 1.2 (0.4–1.9)
Abbreviation: CI, confidence interval. aBoth Msh3 /p53 / (Po0.001)
and p53 / (P¼ 0.001) tumors have significantly more chromosomes per
cell compared with Msh2 /p53 / tumor cells.
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Log2 ratio distributions of gains and losses (Supplementary
Figure S3) and subsequent cluster analysis (Supplementary
Figure S4) revealed that both p53 / and Msh3 /p53 /
lymphomas showed a signiﬁcant increase in CNV (cluster 1)
compared with Msh2 /p53 / tumors (cluster 3). Msh3 /
p53 / and p53 / lymphoma samples clustered together
(cluster 1) that indicates the overall distribution of CNVs
throughout the genome in Msh3 /p53 / tumors was similar
to that of p53 / tumors and that loss of MSH3 does not induce a
speciﬁc pattern of CNV distribution. Interestingly, the Msh3/p53
and p53 sarcoma samples (cluster 2) only showed a moderate
increase in CNV compared with Msh3/p53 and p53 lymphoma
samples. However, the CNV phenotype in Msh3/p53 sarcomas
was signiﬁcantly more severe than that found in Msh2/p53
lymphoma samples. Taken together, these results conﬁrm that
loss of MSH3, but not MSH2, is associated with an increase in
overall CIN in tumor genomes and that the amount of CIN
depends on the underlying predisposing genetic background and
the tissue-speciﬁc context.
DISCUSSION
The MMR proteins MSH2, MSH6, MLH1 and PMS2 all have a major
and well-described role in MMR, and mutations in these genes
have been found in patients with HNPCC/LS. Until now, no
mutations have been found in the other MMR proteins MSH3,
MLH3 and EXO1 that could directly link them to the development
of familial colorectal cancer. Although intestinal tumors developed
in Msh313 and Mlh332 knockout mice late in life, these proteins
appear to have a less pronounced role in MMR and tumor
Figure 3. MSH3 is involved in maintaining chromosomal stability. Examples of spectral karyotypes from lymphoma cells are shown for each
genotype, indicating a close to normal karyotype and t(1,8) for Msh2 /p53 / , increased aneuploidy, del1 and t(1,7) for Msh3 /p53 / ,
and increased aneuploidy, 2del1 and del6 for p53 / . Red boxes indicate translocations and deletions.
Figure 4. Loss ofMsh3 is associated with a high level of CNV. Chromosome copy-number changes were analyzed as described before.42 To account
for tumor heterogeneity, large segments with low-level copy-number changes were considered as important as small segments with high-level
changes, and no arbitrary log2 ratio was used. %, percentage of samples that showed gain (red) or loss (green). L, lymphoma; S, sarcoma.
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suppression. However, they have been implicated in other
processes aside from MMR: apart from their roles in class switch
recombination and somatic hypermutation,33–36 MLH3 is essential
for processing DSBs at crossovers during meiosis,37 and EXO1 has
been identiﬁed as a key mediator of DNA end resection during
DSBR.38 Surprisingly, it has recently been found that MSH3 protein
expression is higher in the majority of murine tissues when
compared with MSH6, suggesting important and speciﬁc roles for
MSH2-MSH3 in DNA repair and genomic instability.24 The similar
phenotype of late-onset tumors with mild MSI that appeared in
Msh3 / and Exo1 / mice led us to hypothesize a role for
MSH3 in tumor suppression via DSBR and maintenance of
chromosomal stability. In this study, we showed that, in mice,
loss of Msh3 leads to accumulation of unrepaired DSBs and to a
shift in tumor spectrum with increased CIN on a p53-driven tumor
predisposing background.
As described before,25 mice with combined Msh2 and p53
ablation show independent segregation of the MSI phenotype
compared with p53 / alone, which suggests that loss of Msh2
is dominant over the p53 / phenotype. Furthermore, their
synergism in tumorigenesis suggests that they are not genetically
epistatic. In contrast, Msh3 /p53 / mice show features that
are more similar to the p53 / phenotype. The lack of synergism
in tumorigenesis and the shift in tumor spectrum toward
sarcomagenesis suggest that MSH3 might not be involved in
tumor initiation but rather in tumor progression by modulating
the p53-deﬁcient phenotype. Interestingly, loss of p53 did not
accelerate gastrointestinal tumorigenesis of Msh3 / mice, as we
only detected a small number of gastrointestinal carcinomas in
Msh3/p53-mutant mice (Figure 1b). As loss of MSH3 is associated
with a variety of human cancer types, its effects might be evident
on other predisposing backgrounds, implicating MSH3 as a
general modulator of cancer phenotypes. The contribution of
Msh3 deletion to tumorigenesis, however, depends on the genetic
context and subsequent mechanism of tumorigenesis in different
tissues, as Msh3 /Apc1638N mice did not show a different tumor
onset or phenotype compared with Apc1638N mice.39
Because of the strong aneuploidy phenotype caused by loss of
p53,40,41 it was not immediately clear whether loss of Msh3
contributed to the increase in CIN in Msh3 /p53 / tumors.
However, although there was only a limited number of tumor
samples available for SKY analysis, we observed differences
between tumors with combined Msh3/p53 deﬁciency and single
p53 deﬁciency with a trend toward an increase in the average
number of translocations per cell for Msh3 /p53 / tumors
compared with p53 / alone, indicating defective DSBR caused
by loss of the MSH2-MSH3 complex in these tumors. This defect in
DSBR was also visible when we counted chromosomal aberrations
in metaphase spreads, showing a signiﬁcant increase in chromatid
breaks in Msh3 / and Msh2 / MEFs. Interestingly, here the
number of translocations was not signiﬁcantly different between
wild-type, Msh3 / and Msh2 / MEFs, which might be due to
technical difﬁculties with scoring translocations in regular
metaphase spreads. Alternatively, these data suggest that loss of
MSH2-MSH3-dependent DSBR results in an increase in the number
of translocations during the clonal outgrowth of p53-deﬁcient
tumors and contributes to p53-driven tumorigenesis. The amount
of CIN represented by CNV, however, is signiﬁcantly increased in
Msh3 /p53þ / tumors (Figure 4 and Supplementary Figure S2)
compared with the CNV phenotype in p53þ / tumors from our
previous study,42 which indicates that loss of Msh3 is contributing
to the CIN phenotype in Msh3 /p53þ / tumors.
Our observations indicate a dual function for the MutSb
complex in genome maintenance and tumor suppression
(Figure 5). Msh2-deﬁcient mice display a strong MMR defect with
accumulation of mutations and low CIN, indicating the essential
role for MSH2 in MMR. On the other hand, a moderate DSBR
defect is associated with the loss of either MSH2 or MSH3, whereas
the mild phenotypes with regard to CIN and tumorigenesis that
are associated with the loss of MSH2-MSH3-dependent DSBR are
difﬁcult to observe in the dominant MMR tumor phenotype of
Msh2-deﬁcient mice, we were able to study them by deleting
Msh3 on the appropriate tumor predisposing background.
Because the DSBR defect is not as severe as the defect caused
by loss of other canonical DSBR proteins, this further suggests a
role for MSH3 in the repair of a subset of DSBs, possibly substrates
of the SSA pathway.6,7 Interestingly, loss of MSH3 was shown to be
associated with accelerated tumor progression in MLH1-deﬁcient
colorectal cancers, and it was suggested that the effect of MSH3
loss on tumor progression might be related to another function of
MSH3 unrelated to MMR, implicating its role in DNA DSBR by SSA.3
It remains unclear whether the role of MSH3 in DSBR is dependent
on its recruitment via the MMR pathway, either during the process
of homeologous recombination or when small insertions/
deletions or DNA mismatches43 on opposite strands are in close
proximity so as to mediate the formation of DSBs during the MMR
process, or whether MSH2-MSH3 could instead be recruited
directly to sites of DSBs. Regardless, MSH3 was shown to co-
localize with gH2AX and DSB foci following genotoxic stress,44,45
which suggests that it might be directly involved in a subset of
DSBR events.
Despite the moderate defect in DSBR, Msh3-deﬁcient mice
showed a signiﬁcant increase in sarcomagenesis, suggesting that
loss of MSH3 targets sarcoma tumor suppressor genes and
modulates p53-dependent tumorigenesis. When we analyzed
lymphomas and sarcomas for genomic instability, Msh3 /
p53 / and p53 / lymphomas showed the largest increase in
CNV, whereas Msh2 /p53 / mice displayed a low CNV
phenotype. Interestingly, both Msh3/p53 and p53 sarcomas
displayed signiﬁcantly more CNV than Msh2/p53 lymphomas,
but less CNV than Msh3/p53 and p53 lymphomas, and clustered
together based on their moderate CNV proﬁle. This indicates that
loss of Msh3 causes a repair defect that contributes to genomic
instability in a tissue-speciﬁc manner and promotes p53-driven
sarcomagenesis. As the sarcomas in our mouse cohorts are
microsatellite stable, the increase in sarcoma incidence in Msh3/
p53 mutant mice is likely caused by loss of Msh3-dependent
DSBR that contributes to the moderate CIN that is associated
with sarcomagenesis. However, loss of Msh3-dependent MMR
Figure 5. Model representing different functions of the Mutsb
(MSH2-MSH3) complex. Deletion of Msh2 induces a strong MMR
defect and a moderate DSBR defect, leading to a dominant tumor
phenotype with early-onset tumors that are MSI-high and chromo-
somally stable. Deletion of Msh3 revealed a moderate DSBR defect
next to the previously described moderate MMR defect, resulting in
a modulated tumor phenotype of late-onset tumors that were MSI-
low and showed increased CIN.
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might also have a role in p53-dependent sarcomagenesis by
resulting in a low-level mutator phenotype involving base
substitutions that might be difﬁcult to detect.2,43
In conclusion, our data indicate for the ﬁrst time that the MSH2-
MSH3 protein complex is involved in tumorigenesis through
maintenance of chromosomal stability. In contrast to the MutSa
complex (MSH2-MSH6), which has a dominant role in genome
maintenance by MMR, MSH2-MSH3 functions both in MMR,
indicated by an MSI-L phenotype, and DSBR, as has been recently
shown in yeast.7 Loss of MSH3 can therefore contribute to
tumorigenesis in two ways: by a mild MMR defect leading to MSI-L
and low-level mutation accumulation and by a DSBR defect that
leads to a moderate increase in CIN. As most sporadic colorectal
cancers are CIN (85%),46 the MSH2-MSH3 complex might have an
important role in suppression of late-onset sporadic cancers that
are MSI-L. Future studies should therefore include the analysis of
Msh3 loss on multiple tumorigenic backgrounds to assess a more
speciﬁc role for MSH3 in tumorigenesis.
MATERIALS AND METHODS
Animals, tumors and survival
Msh2 / , Msh3 / and Msh6 / knockout mice were previously
generated in our lab.13,28,47 p53 / knockout mice48 were purchased
from Jackson Laboratories (Bar Harbor, ME, USA). All mice were on a
congenic C57BL/6 background. Mice were intercrossed as described and
observed until they became morbid or moribund. Tumors were removed
and ﬁxed in 10% buffered formalin or frozen at  150 1C. After parafﬁn
embedding of ﬁxed tissue, sections were stained with hematoxylin and
eosin. Statistical analysis of tumor incidence was completed using IBM
SPSS Statistics version 20.0 (IBM Corp., Armonk, NY, USA). The Kaplan–
Meier method was used to compare curves for survival, with signiﬁcance
evaluated by two-sided log rank statistics. A w2-test was used to assess the
inﬂuence of genotype on the tumor spectrum.
Microsatellite instability, LOH and mutational analysis of p53
For MSI analysis, the D7Mit91 and D17Mit123 microsatellite loci were
ampliﬁed from normal and tumor DNA and analyzed as previously
described.39 Tumor DNA was also serially diluted and analyzed for loss of
the wild-type p53 allele as previously described.42 To analyze tumors for
p53 mutations, primers amplifying all exons of p53 (including both
transcript variants of exon 11) were used as described,49 followed by DNA
sequencing.
Chromatid break and double-strand break analysis
Primary MEFs (p4-6) were treated overnight with 0.1mg/ml colcemid
(Invitrogen, Carlsbad, CA, USA) and subsequently swelled, ﬁxed and
dropped onto glass slides to prepare metaphase spreads. DNA was stained
using mounting medium with DAPI (Vector Laboratories, Inc., Burlingame,
CA, USA), and at least 100 metaphases in 2–3 different cell lines were
analyzed per genotype.
For DSB analysis, MEFs were cultured on poly-L-lysine-coated slides
(Sigma, St Louis, MO, USA), irradiated with 1Gy and incubated at 37 1C for
30min to 6 h. Cells were ﬁxed with cold 1:1 methanol:acetone for 5min,
and washed twice with cold PBS for 5min. After blocking with 10% FBS in
PBS, cells were incubated overnight with a mouse monoclonal gH2AX
antibody (Upstate, Billerica, MA, USA; 1:500). Cells were again washed twice
in cold PBS for 5min and incubated for 1 h at room temperature with an
Alexa Fluor 488-labeled goat anti-mouse antibody (Invitrogen). DNA was
stained using mounting medium with DAPI. The experiment was repeated
three times for two different cell lines per genotype, and a minimum of
100 cells were analyzed each time.
Metaphases and foci were counted using an Olympus BX61 microscope
(Olympus America Inc., Center Valley, PA, USA) with Sensicam QE cooled
CCD camera (PCO, Kelheim, Germany). Signiﬁcant differences between cell
lines in the number of breaks or gH2AX foci were calculated using an
independent two-sample t-test of equal variance.
Spectral karyotyping
Thymic lymphomas were dissociated, ﬁltered and resuspended as
described.50 To prepare metaphase spreads, cells were treated with
colcemid for 3–6 h, swelled, ﬁxed and dropped onto clean glass slides
inside a humidity chamber. SKY was performed as previously described.51
Slides were hybridized with the combinatorially labeled whole
chromosome painting probes (Applied Spectral Imaging, Inc., Carlsbad,
CA, USA), and metaphase images were captured using the Applied Spectral
Imaging interferometer on an epiﬂuorescence microscope (Carl Zeiss
Microscopy, Thornwood, NY, USA). SKY karyotypes were then analyzed
with SkyView version 1.62 (Applied Spectral Imaging, Inc.). Metaphases
were captured and analyzed using the nomenclature approved by the
International Committee on Standardized Genetic Nomenclature for Mice
(http://www.informatics.jax.org).
Array comparative genomic hybridization
Genomic DNA was isolated from frozen tumor tissue and matched normal
tail tissue using the Qiagen DNeasy kit and hybridized to NimbleGen
Mouse CGH 3 720K Whole-Genome Tiling Arrays (Roche NimbleGen, Inc.,
Madison, WI, USA) in four different experiments. To represent the wide
variation of mouse sarcoma samples but also to homogenize between
genotypes, groups were composed of one ﬁbrohistiocytic, one hemangio-
and one spindle cell sarcoma each.
Plotting summaries of copy-number changes among all samples for
each genotype was done as described before.42 In order to compare copy-
number changes between different sets of samples, distributions of the
(log2) ratios for the segmented data were plotted for each sample. The tails
of this distribution (weight) were used to indicate the amount of CIN; that
is, for each distribution, the proportion of data points 43 s.d. of the
distribution with the lowest variance was computed on the left and right
tails, that is, relative copy-number increase (gain) or decrease (loss)
according to the aCGH data. Samples were subsequently clustered using
the k-means clustering algorithm. Consistency of the clusters obtained was
evaluated using the silhouette method.52
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